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Chemokine Receptor Expression by Leukemic
T Cells of Cutaneous T-Cell Lymphoma: Clinical
and Histopathological Correlations
Elisabetta Capriotti1, Eric C. Vonderheid2, Christopher J. Thoburn3, Emilie C. Bright3 and Allan D. Hess3
Chemokine receptors expressed by normal and neoplastic lymphocytes provide an important mechanism for
cells to traffic into the skin and skin-associated lymph nodes. The goal of this study was to correlate chemokine
receptor and CD62L expression by circulating neoplastic T cells with the clinical and pathological findings of the
leukemic phase of cutaneous T-cell lymphoma, primarily Se´zary syndrome (SS). Chemokine receptor mRNA
transcripts were found in the majority of leukemic cells for CCR1, CCR4, CCR7, CCR10, CXCR3, and CD62L and
in 20–50% of the samples for CXCR5. In patients with SS, relatively high expression levels of CCR7 and CCR10 by
circulating neoplastic T cells correlated with epidermotropism, CXCR5 expression correlated with density of the
dermal infiltrate, and CD62L correlated with extent of lymphadenopathy. Of note, CXCR5 expression and a
dense dermal infiltrate correlated with a poor prognosis. The chemokine receptor profile supports the concept
that neoplastic T cells are central memory T cells, and that CCR10 and CD62L play a fundamental role
respectively in epidermotropism and lymphadenopathy that is observed in SS.
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INTRODUCTION
The cutaneous T-cell lymphoma (CTCL) spectrum is composed
of mycosis fungoides (MF), Se´zary syndrome (SS), and other
T-cell lymphomas that have initial manifestations in the skin
(Willemze et al., 2005). SS is now defined as erythrodermic
CTCL with ‘‘leukemic’’ blood involvement (Vonderheid et al.,
2002). In our experience, each of the hematologic criteria for
SS (B2 blood rating), which have been proposed by the
International Society for Cutaneous Lymphomas (ISCL) defines
patients with a worse prognosis compared to erythrodermic
CTCL patients who lack these criteria (Vonderheid and
Bernengo, 2003). Because some patients with extensive
nonerythrodermic MF may also have blood findings similar
to SS, we use the inclusive term ‘‘leukemic phase of CTCL’’ to
include patients with SS and MF who meet the B2 blood rating
defined by the ISCL (Vonderheid et al., 2002).
Leukocyte migration into inflammatory sites is mediated
by 8–10 kDa proteins known as chemokines, short for
‘‘chemotactic cytokines’’. These chemokines are classified
into four groups, depending on the spacing between two
N-terminal cysteine residues: the CXC (a-chemokine
subfamily), CC (b-chemokine subfamily), XC, and CX3C
chemokines (Bacon et al., 2002). The ligands for these
chemokines are classified by appending an R and a number
to the chemokine nomenclature, that is CC, CXC, XC, or
CX3C followed by R for receptor and then a number.
Homeostatic receptors include CCR4, CCR7, CCR9, CXCR4,
and CXCR5, and inflammatory/inducible chemokine recep-
tors include CCR1, CCR2, CCR3, CCR5, CCR6, CCR8,
CXCR1, CXCR2, CXCR3, CXCR6, and CX3CR1. Of these
CCR7 and CXCR4 are highly expressed by naı¨ve (antigen-in-
experienced) T cells, and in addition, CCR2, CCR4, CCR5,
CCR6, CCR10, CXCR3, CXCR5, CXCR6, and CX3CR1
become expressed by subsets of memory CD4þ T cells.
The molecular events that underlie T-cell localization
within the dermis and epidermis have been reviewed (Scho¨n
et al., 2003; Ebert et al., 2005). Skin-homing lymphocytes are
characterized by expression of cutaneous lymphocyte-asso-
ciated antigen (CLA/CTAGE1). The interaction between CLA
and E-selectin that is upregulated by endothelial cells of the
superficial dermal plexus during inflammation causes CLA-
bearing lymphocytes to roll along the vessel, and permits
additional molecular interactions including chemokine-
mediated conversion of low- to high-affinity integrins to
occur that promote firm binding to the vessels wall and
transmigration through the vessel into the dermis (diapedesis).
In addition, in chronic T-cell-mediated skin diseases includ-
ing CTCL, endothelial cells can develop morphologic features
of high endothelial venules (HEVs), which might provide
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another mechanism for aberrant trafficking of CD62L-bearing
naı¨ve T cells, central memory cells, and potentially neoplas-
tic T cells of CTCL into the skin (Michie et al., 1993;
Lechleitner et al., 1999). Chemokines secreted by dermal and
epidermal cells direct T-cell migration to other regions in the
skin.
The aim of this study is to assess whether chemokine
receptor gene expression measured by real-time quantitative
PCR (qPCR) correlates with the clinical and pathological
findings of the leukemic phase of CTCL.
RESULTS
Chemokine receptor mRNA transcripts were found in the
majority of leukemic cells for CCR1, CCR4, CCR7, CCR10,
and CXCR3, and in 20–50% of the samples for CXCR5.
(Figure 1, Table 1) The remaining gene transcripts (CCR5,
CCR6) were not detected or infrequently expressed by
neoplastic cells. Transcripts for CD62L were found in 18
samples.
Although hindered by cell death and nonspecific staining
on stored samples, the expression mRNA transcript levels
correlated well with protein expression of CXCR3 as
determined by flow cytometry on nine samples. (Figure 2)
This provides evidence that mRNA transcript levels in
unmanipulated (i.e., activated) leukemic CTCL cells reflects
the degree of protein expression in most instances as has been
reported for HUT78 cell lines (Notohamiprodjo et al., 2005).
Correlation to skin histopathology
The expression of several chemokine receptors and CD62L
by neoplastic cells was correlated to skin histopathologic
findings for a subset of 23 patients with SS on whom skin
biopsy specimens taken at the time of blood sampling were
available (Tables 2 and 3). For CCR1, CCR4, CXCR3, CXCR5,
and CD62L, which were expressed in 15, 11, 16, 10, and 14
of the cases, respectively, the presence or absence of
transcripts were compared against the dermal pattern of
infiltration (perivascular vs band-like7interstitial infiltrate)
and the degree of epidermotropism (absent vs basal layer vs
diffuse). For CCR7 and CCR10, which were expressed in most
cases, the cases were divided into relatively low (less than
median expression values) and high (median or higher
expression values).
Regarding the pattern of dermal infiltration, no correlation
was found for any of the markers except for CXCR5 which
was expressed by neoplastic T cells in 10 of 16 cases with a
heavier dermal infiltrate compared to none of seven cases
with a perivascular infiltrate (Fisher’s test, P¼0.007). With
regards to epidermotropism, relatively high expression of
CCR7 and CCR10 positively correlated with the magnitude of
epidermal infiltration. High CCR7 expression by circulating
neoplastic T cells occurred in only one of five (20%) cases
without epidermal involvement, 4 of 10 (40%) cases with
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Figure 1. Real-time quantitative PCR performed on peripheral blood
samples from 28 patients with leukemic phase of CTCL and 5 healthy
controls. The expression levels of chemokine receptor and CD62L transcripts
relative to a control gene (GADPH) are graded as defined in the legend of
Table 1.
Table 1. Expression levels of chemokine receptor and
CD62L gene transcripts in neoplastic cell samples
from the leukemic phase of cutaneous T-cell
lymphoma1
PT CCR1 CCR4 CCR5 CCR6 CCR7 CCR10 CXCR3 CXCR5 CD26L
1 + 0 0 0 + + + 0 +
2 0 0 0 0 + + 0 0 0
3 + ++ 0 0 + + + + +
5 0 0 0 0 + + 0 0 0
6 + +++ 0 0 + + + 0 +
7 0 0 0 0 + + + 0 0
8 + 0 0 0 + + ++ + 0
9 + 0 0 0 0 +++ 0 + +
10 + + 0 ++ + + + + +
11 + + 0 0 + + + 0 +
13 + 0 0 0 + + + + +
14 + 0 0 0 ++ + +++ 0 0
15 0 0 0 0 0 ++ 0 0 0
16 + 0 0 0 0 ++ 0 + +
17 + + 0 0 + + + + +
18 + + 0 0 + + + 0 +
20 + + 0 0 + + + 0 0
21 + + 0 0 + + + + +
22 0 0 0 0 + + + 0 0
23 + + 0 0 + + + 0 +
24 + + 0 0 + + + 0 +
25 0 0 0 0 + + 0 0 0
26 0 ++ 0 0 + + ++ + 0
27 + + 0 0 + 0 + + +
28 + ++ 0 0 + + + + +
29 + 0 0 0 ++ + 0 + +
302 + + + + + + + + +
312 0 ++++ ++ +++ +++ + + + ++++
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
1Gene/GAPDH transcripts: 0, not detected; +, gene expression less than
10-fold of GAPDH expression; ++, gene expression 10- too100-fold that
of GAPDH; +++, gene expression 100 too1,000-fold that of GAPDH,
++++, gene expression 1,000 or more that of GAPDH.
2Recently collected samples.
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cells located along the basal layer only, and seven of eight
(88%) cases with a more diffuse epidermal infiltration
(w2 exact test, P¼ 0.045). Likewise, high CCR10 expression
was associated with 0 of 5 cases without epidermal infiltration,
5 of 10 (50%) with involvement of the basal layer only, and
seven of eight (88%) of biopsies with diffuse epidermal
involvement (w2 exact test, P¼0.007).
Correlation with lymphadenopathy
The correlation between CD62L expression and lymphadeno-
pathy is of interest, considering the key role that CD62L plays
in T-cell entry into lymph nodes by initially tethering to
peripheral node addressin expressed by HEVs (Table 2).
CD62L transcripts were present in 14 of 18 (78%) samples
obtained from patients with clinically enlarged lymph nodes
versus two of seven (29%) samples from patients without
enlarged nodes (Fisher’s test, P¼0.058). In addition, there
was a positive trend between CD62L expression and extent of
lymphadenopathy based on the presence of palpable lymph
nodes in the cervical, axillary, and inguinal/femoral regions
(w2, P¼0.085). However, no difference in CD62L expression
was noted between cases with palpably small versus large
lymph nodes (Fisher’s test, P¼ 0.524), nor for the cases
undergoing a lymph node biopsy with the specimen classified
as non-effaced (n¼6) or effaced (n¼5 cases) nodal
architecture (Fisher’s test, P¼ 1.0).
Although CCR7 is recognized to be the major chemokine
receptor involved in recruiting T cells from the vasculature into
lymph nodes, and CCR7 transcripts were found in 89% of
samples from patients with SS, no correlation was found
between between presence or absence of lymphadenopathy
(Fisher’s test, P¼1.0), extent of lymph node enlargement
(w2, P¼0.405) nor maximum lymph node size (w2, P¼0.845)
for cases with relatively low versus high (defined as less than
median vs median or higher transcripts) CCR7 expression levels.
Correlation with other measures of tumor burden
In addition to skin biopsy findings and lymphadenopathy,
Se´zary cell counts and serum lactic acid dehydrogenase
(LDH) levels were available on all 25 patients with SS
(Table 4). When the percentage of Se´zary cells within the
lymphocyte population was correlated to the level of
chemokine receptor and CD62L transcript levels using the
Spearman rank test, only CCR10 and CXCR3 were signifi-
cantly correlated, that is CCR10 was positively correlated
(r¼ þ0.405, P¼0.044), whereas CXCR3 was inversely
correlated (r¼0.562, P¼0.004). In addition, a signifi-
cantly higher absolute Se´zary cell count was associated with
cases in which the expression of CCR10 was relatively high
(Xthe median value) versus cases with lower values (less
than the median value) of CCR10 expression (Mann–Whitney
test, P¼ 0.008), and conversely, absolute Se´zary cell counts
were significantly lower in cases in which transcripts for
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Figure 2. Flow cytometry performed on 9 blood samples of leukemic CTCL
selected for low (circle), medium (square) and high (triangle) expression
levels of CXCR3. A positive correlation was found between mRNA transcript
levels and surface protein expression of CXCR3.
Table 2. Histopathologic findings of skin specimens
and lymphadenopathy in patients with SS
PT
Epidermal
infiltration1
Dermal
infiltration2
Maximum LN
size (cm) LN extent3
1 +1 +1 1 A
2 +2 +1 2 A
3 +2 +2 None None
5 +2 +2 None None
6 +2 +1 2 C, A, I
7 +1 +2 3 A, I
8 0 +2 None None
9 +1 +2 2 A
10 0 +2 None None
11 0 +1 3 A, I
13 ND ND 3 A, I
14 +1 +2 3 A
15 +1 +2 None None
16 +1 +2 2 C, A
17 ND ND 3 A, I
18 +1 +1 2 A
21 0 +2 3 A, I
22 +2 +2 0 None
23 0 +1 1 A, I
24 +1 +1 1 A
25 +2 +2 2 A
26 +2 +2 0 None
29 +2 +2 6 C, A, I
30 +1 +2 1 C, A
31 +1 +2 4 C, A, I
LN, lymph node; ND, not done; SS, Se´zary syndrome.
1Epidermal infiltration: 0=no epidermal involvement, +1=lymphocytes
localized to basal layer, +2=lymphocytes at basal and suprabasal
layers7Pautrier microabscesses.
2Dermal infiltration: +1=perivascular involvement, +2=band like7-
interstitial involvement.
3Extent of lymph nodes: palpable LNs in C, cervical; A, axillary; and I,
inguinal regions.
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CXCR3 (Mann–Whitney test, P¼0.005) were detected in the
blood sample compared to those samples without transcripts.
The most likely explanation for these observations is that
circulating neoplastic T cells are predominantly CCR10þ
CXCR3. However, the correlation between CCR10 and
CXCR3 transcript levels in our samples was not significant
(r¼0.198, P¼0.338). No correlation was found between
serum LDH levels and transcript levels for any of the genes
that were studied.
Correlation with survival
No significant correlations were found between survival
curves for presence or absence of transcripts for CCR1, CCR4,
CXCR3, and CD62L, nor for relatively low and high transcript
levels of CCR7 and CCR10. However, the 12 cases of SS with
detectable CXCR5 transcripts had a significantly worse
prognosis than 13 cases without CXCR5 expression (Figure 3).
Other parameters associated with an adverse prognosis for
this cohort of Se´zary patients included a high density of the
dermal infiltrate, but not epidermal involvement, in skin
specimens (n¼23, P¼ 0.008), absolute Se´zary cell count
(P¼0.011), and serum LDH level (P¼ 0.008). The patients’
ages at the time of sample collection, presence of enlarged
lymph nodes, maximum size of palpable lymph nodes, or
extent of lymphadenopathy had no prognostic implications
for this subset of patients. Notably, CXCR5 expression and
LDH level, but not absolute Se´zary cell count, retained
independent significance when subjected to multivariate
analysis in the Cox proportional hazards model. Furthermore,
no differences were found between CXCR5-positive and
CXCR5-negative subsets for patients’ median ages, absolute
lymphocyte and Se´zary counts, CD4/CD8 ratio, and LDH
level. It is therefore possible that the previously noted
correlation between CXCR5 expression and degree of dermal
infiltrate, another parameter with prognostic importance,
may provide an explanation for the association of CXCR5
expression with prognosis.
DISCUSSION
The study provides initial evidence that circulating neoplastic
cells of patients with advanced CTCL express chemokine
receptor message using real-time qPCR. Unfortunately, the
quality of the stored cells precluded concurrent measurement
of surface protein expression in most cases. Therefore, these
expression profiles ideally should be validated on freshly
isolated T-cell subsets that typically contain neoplastic cells
such as CD4þCD26 (Bernengo et al., 2001; Sokolowska-
Wojdylo et al., 2005b; Fierro et al., 2005b), or neoplastic
cells identified by an anti-T-cell receptor Vb antibody
(Gorochov et al., 1995; Morice et al., 2006), or CD158/
KIR3DL2. (Poszepczynska-Guigne et al., 2004). Neverthe-
less, the fact that we performed qPCR on cases of CTCL that
had high blood tumor burdens and the observation that a
strong correlation exists between chemokine receptor CCR7,
CCR10, CXCR3, and CXCR5 mRNAs and surface protein in
CTCL-derived HUT78 cell line suggests that our findings at
the gene expression level has relevance in terms of surface
protein expression except when the gene expression level is
quite low. (Notohamiprodjo et al., 2005) Accordingly, our
findings will be discussed in the context of the surface
expression of corresponding proteins detected in skin lesions
or blood by immunohistochemistry or flow cytometry (FC)
Table 3. Correlation of chemokine receptor and CD62L expression by circulating neoplastic T cells with
histopathologic findings in concurrent skin specimens in 23 patients with SS
Dermal infiltration Epidermal infiltration
Marker1 Expression Perivascular Band-like7interstitial P-value2 Absent Basal layer Diffuse P-value3
CCR1 Present 6 9 0.345 5 7 3 0.090
Absent 1 7 0 3 5
CCR4 Present 5 6 0.193 4 4 3 0.283
Absent 2 10 1 6 5
CCR7 High 3 9 0.667 1 4 7 0.045
Low 4 7 4 6 1
CCR10 High 2 10 0.193 0 5 7 0.007
Low 5 6 5 5 1
CXCR3 Present 6 10 0.366 5 7 4 0.191
Absent 1 6 0 3 4
CXCR5 Present 0 10 0.007 3 4 3 0.748
Absent 7 6 2 6 5
CD62L Present 6 8 0.167 4 7 3 0.298
Absent 1 8 1 3 5
SS, Se´zary syndrome.
1Because CCR7 and CCR10 expressed in most samples, correlations made with relatively high expression levels (transcript levelsXthe median value).
2Fisher’s exact test.
3Pearson’s w2 exact test.
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reported by others (Jones et al., 2000; Lu et al., 2001;
Ferenczi et al., 2002; Kallinich et al., 2003; Yamaguchi et al.,
2003; Ishida et al., 2004; Notohamiprodjo et al., 2005;
Sokolowska-Wojdylo et al., 2005a, b; Fierro et al., 2006;
Narducci et al., 2006; Yagi et al., 2006).
CCR1
CCR1 transcripts were detected in 74% of the cases assessed
in the present studies. Interestingly, surface expression of the
CCR1 protein was not demonstrated by FC on circulating
neoplastic cells in 12 cases of SS, recently reported by
Narducci et al. (2006) and could not be detected in tumor
cells infiltrating into the skin in 12 cases of MF studied by
Kallinich et al. (2003). Thus, a discrepancy appears to exist
between CCR1 mRNA expression in our samples and surface
protein expression reported by others.
Although CCR1 gene transcription levels in neoplastic
T cells of our cases were often increased relative to normal
Table 4. Laboratory studies in patients with the leukemic phase of CTCL
PT2 A G DIAG
ABSLYM
(K/L)
SZ
(%)
ABSSZ
(mm3) CLONE CHR
CD3
(%)
CD4/CD8
(ratio)
CD4+7
(%)
CD4+26
(%) Vb (%)
LDH
Index6
1 68 F SS 1.19 30 357 + (S) + 63 47/13 (3.6) 35 11 31 0.81
2 44 F SS 3.13 61 1,909  (P)5 5 94 83/9 (9.2) ND ND ND 0.95
3 82 M SS 3.15 34 1,071 + (S) + 60 50/8 (6.3) 56 53 ND 0.69
5 73 F SS 6.27 62 3,889 + (P) + 85 72/13 (5.5) 19 48 NR 0.78
6 69 F SS 4.00 21 840 + (P) + 88 78/8 (9.8) 72 65 72 1.35
7 69 M SS 9.83 24 2,359 + (S,P)  95 94/1 (94) 64 92 90 0.88
8 79 F SS 3.42 42 1,438 + (S) + 77 67/13 (5.2) ND ND ND 1.18
9 80 M SS 6.72 84 5,645  (P) + 95 94/1 (94) 15 75 79 2.53
10 60 F SS 1.94 27 525 + (P) + 82 75/5 (15) 1 0 80 0.89
11 41 F SS 3.44 53 1,823 + (S) + 94 91/0.4 (4100) 30 92 59 2.23
13 69 F SS 6.32 22 1,391 + (S,P) + 77 75/1 (75) 23 61 66 1.15
14 71 M SS3 1.72 35 660 + (S) + 46 80/5 (16) 38.6 22.9 ND 1.34
15 69 M SS 1.67 71 1,189 + (S) + 85 76/6 (12.7) 64 62 48 0.84
16 85 F SS 18.35 67 22,011 + (P) + 98 93/5 (18.6) 2 91 NR 1.71
17 80 M SS3 19.49 53 10,330 + (P) + 98 91/6 (15.2) 11 91 83 1.23
18 83 F SS 1.33 37 492 + (P)  72 65/2 (37.5) 14 37 28 1.37
20 74 F MFT 3.61 32 1,156 + (P) + 94 86/8 (10.8) 81 86 78 1.77
21 54 M SS 2.13 50 1,066 + (S,P) + 91 85/5 (17) 78 74 75 0.92
22 70 F SS 30.63 50 15,314 + (S) + 97 96/0.3 (4100) 95 93 NR 2.95
23 31 F SS 0.77 50 385  (S,P)5 5 88 82/8 (10.3) ND ND ND 0.93
24 60 F SS 1.72 46 789 + (S) + 88 84/3 (28) 81 78 78 2.09
25 86 F SS 60.91 64 37,901 + (S) + 98 99/0.4 (4100) 93 99 97 2.76
26 73 F SS 4.74 68 3,225  (P) + 73 79/10 (7.9) ND ND ND 1.13
27 72 F MFPQ 5.76 28 1,614  (S) + 95 84/7 (12) 16 81 46 0.76
28 45 F PTL4 1.25 15 188  (P) + 16 70/4 (17.5) ND ND ND 0.66
29 52 M SS 102.22 91 93,020 + (S) + 99 98/0.4 (4100) 67 99 97 3.09
30 66 M SS 3.14 26 816  (P) ND 75 86/3 (28.7) 75 69 ND 1.27
31 62 M SS 4.28 56 2,399 + (P) + 97 8/2 (49) 76 82 ND 1.63
ABSLYM, absolute lymphocyte count; ABSSZ, absolute Se´zary cell count; AG, age and gender of patient; CLONE, molecular evidence of a T-cell clone by
Southern blot (S) or PCR (P); DIAG, clinical diagnosis; LDH, lactic acid dehydrogenase; SZ, Se´zary cells/100 lymphocytes.
1Diagnosis of Se´zary syndrome rendered if erythrodermic CTCL and at least one criterion for leukemic blood involvement per recommendations of the ISCL.
(Vonderheid et al., 2002).
2Cases 4, 12, and 19 excluded because GADPH failed to amplify.
3Se´zary syndrome preceded by MF (secondary SS).
4Cutaneous plaques and nodules with histologic features suggestive of Kimura’s disease; abnormal T cells in blood with CD2+CD3CD4+CD7CD8
immunophenotype.
5Features of erythrodermic CTCL with abnormal cells in the blood by FC, later fulfilling criteria for SS; negative for T-cell clone at time of cell collection,
positive later in course.
6LDH index=LDH value/top normal for laboratory reference range.
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lymphocytes (Figure 1), the transcription levels were rela-
tively low compared to most other chemokine receptors. It is
plausible that CCR1 expression levels in neoplastic T cells are
not high enough to yield surface protein levels that are
detectable by immunohistochemistry or FC. Alternatively,
post-translational processing of mRNA may interfere with
surface expression of the CCR1 protein or there may be rapid
clearing of CCR1 protein from the cell surface.
CCR4
The results for CCR4 indicate that transcript levels are not
uniformly present in samples of SS, that is only 15 (54%)
cases, but when present the level of expression exceeded that
of normal subjects in all instances. (Figure 1, Table 1) Indeed,
a 410-fold increase in CCR4 transcripts was detected in
neoplastic cells in 13 of the 15 positive cases compared to
normal cells. Nevertheless, the absence of CCR4 expression
in a substantial portion of our patients was unexpected
considering the fact that surface protein expression of CCR4
on neoplastic cells of SS has been consistently demonstrated
in a number of studies (Ferenczi et al., 2002; Sokolowska-
Wojdylo et al., 2005a; Fierro et al., 2006; Narducci et al.,
2006; Yagi et al., 2006). In particular, Narducci et al. (2006)
found CCR4 protein expression to range from 31 to 100%
(median, 90%) of CD4þVbþ neoplastic cells from 12 cases
of SS studied by FC. Furthermore, Fierro et al., 2006 found
CCR4 to be frequently expressed on CD4þCD26 lympho-
cytes in SS (n¼ 20, mean, 59.1%, SD, 18.6%) compared to
CD4þCD26 lymphocytes in benign inflammatory erythro-
dermas (n¼ 25, mean, 11.5%, SD, 7.4%) and healthy
controls (n¼ 24, mean, 16.6%, SD, 4.5%). These authors
proposed that the CD4þCCR4þCD26 phenotype can be
used to differentiate SS from inflammatory erythrodermas.
The reason why CCR4 transcripts were absent on a subset
of our leukemic CTCL cases is unclear. It is possible that
CCR4 mRNA is especially labile and prone to degradation
(long-term storage may have contributed to this) or that CCR4
surface protein may have a long half-life on the cell
membrane even when its gene is downregulated. Another
consideration is that neoplastic cells expressing relatively
high levels of CCR4 mRNA and hence proteins on the cell
surface might preferentially sequester in the skin, leaving
behind cells in the blood with relatively low expression
levels. However, this hypothesis is unlikely, considering that
Fierro et al. (2006) found CCR4 expression to be lower on
CD4þCD26 cells elaborated from the skin lesions of
Se´zary patients compared to the blood.
CCR7
CCR7 transcripts were detected in 25 of 28 (89%) patients in
this series, and high levels of expression (410-fold increase
over normal control values) were observed in 10 patients.
Surface expression of CCR7 protein has been found in all
cases of SS reported thus far (Sokolowska-Wojdylo et al.,
2005a; Narducci et al., 2006), and like CCR4, the proportion
of neoplastic cells with CCR7 protein on the surface varies
among cases. For example, for patient 1 with SS reported by
Sokolowska-Wojdylo et al. (2005a), 93% of the circulating
cells expressed Vb2, but only 46% of the cells expressed
surface CCR7. In the series of SS studied by Narducci et al.
(2006), the percentage of CCR7 on Vbþ cells ranged from 24
to 97% (median, 82%). CCR7 surface protein also was
reported to be expressed in the tumor phase of MF (Kallinich
et al., 2003).
CCR10
At the mRNA level, CCR10 transcripts were detected in all
but one of our patients with leukemic CTCL, and CCR10
transcripts were increased 410-fold over normal levels in 23
of the 27 (82%) positive samples. In fact the average increase
over normal values was greater for CCR10 than any other
chemokine receptor that we evaluated.
CCR10 has recently be reported to be expressed in the skin
and blood of SS. (Notohamiprodjo et al., 2005; Sokolowska-
Wojdylo et al., 2005a; Fujita et al., 2006). As with CCR7, it
appears that CCR10 protein is expressed on a proportion of
circulating neoplastic cells in SS. For example, in the paper
by Sokolowska-Wojdylo et al. (2005a), 55% of the lympho-
cytes expressed CCR10 from a patient with nearly all
neoplastic cells in the blood. Fujita et al. (2006) also found
that the number of circulating CD4þCCR10þ cells was
significantly higher in MF than controls, even during the early
stages. CCR10 mRNA and surface protein are expressed by
CTCL-derived HUT78 cells (Notohamiprodjo et al., 2005).
Therefore, the results of the present studies are in agreement
with published reports that neoplastic T cells of MF/SS
consistently express CCR10. It is worth noting that 11 of 25
(44%) patients in this series with a chromosomally abnormal
clone in the blood had evidence of an isochromosome 17
that could potentially result in an increase in copies of CCR10
because this gene is located on the long arm of chromosome
17 (17q21.1–q21.3). However, no difference in CCR10
transcript levels was found for cases with (n¼11) or without
(n¼14) an isochromosome 17 (P¼ 0.412).
CXCR3
Evaluation of CXCR3 gene expression revealed the mRNA
transcripts for this receptor was detected in 75% of the
samples, and that 16 of the 21 (76%) positive cases had
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Figure 3. Survival curves for 25 patients with SS. The prognosis is worse
when circulating neoplastic cells express transcripts for CXCR5 compared to
CXCR5-negative cases.
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transcript levels 410-fold compared to normal controls.
Immunohistochemical studies have demonstrated that
CXCR3 is expressed by neoplastic cells in skin lesions of
MF/SS, but like CCR4, the proportion of positive cells varied
considerably among in individual cases (Jones et al., 2000;
Lu et al., 2001; Kallinich et al., 2003; Yamaguchi et al., 2003;
Notohamiprodjo et al., 2005; Yagi et al., 2006).
In general, CXCR3 expression was found in less than 50%
of the neoplastic cells in involved skin of MF/SS in about
half of the reported cases from the literature (Jones et al.,
2000; Lu et al., 2001; Kallinich et al., 2003; Notohamiprodjo
et al., 2005; Yagi et al., 2006). Of interest, Yagi et al. (2006)
found CXCR3 to be expressed in more than 40% of neo-
plastic T cells in 20/26 (77%) cases of MF, but none of five
cases of SS. In one Se´zary patient, FC on the skin infiltrate
confirmed that Vb9þ neoplastic T cells expressed CCR4 but
not CXCR3. Several of these studies showed that CXCR3
expression was expressed by small neoplastic cells and often
lost by large neoplastic cells in skin infiltrates or lymph
nodes with histologic evidence of large-cell transformation,
suggesting that loss of CXCR3 might be an important factor
in dissemination of the disease (Jones et al., 2000; Lu et al.,
2001; Kallinich et al., 2003; Yamaguchi et al., 2003; Yagi
et al., 2006). CXCR3 mRNA and surface protein are highly
expressed by CTCL-derived HUT78 cells (Notohamiprodjo
et al., 2005).
Conversely, using FC, Narducci et al. (2006) found CXCR3
protein to be expressed on CD4þVbþ neoplastic cells in 11
of 12 patients, but at low levels ranging from 1 to 52%
(median, 7%). By comparison, the mean CXCR3 protein
expression for normal donor cells was 35% (SD, 9%).
Likewise, Fierro et al. (2006) found CXCR3 protein to be
expressed on about 8% of CD4þCD26 cells in the blood
of SS, respectively, compared to a similar percentage of
CD4þCD26 cells in the blood of various benign erythro-
dermas. These studies indicate that circulating neoplastic
cells typically express low levels of CXCR3 in SS.
CXCR5
Low transcript levels for CXCR5 were detected in 14 (50%) of
the leukemic samples. This contrasts with the consistent
absence of CXCR5 surface protein by neoplastic T cells in
skin lesions of MF including four cases studied for CXCR5
expression by reverse transcriptase PCR and in situ hybridiza-
tion (Kallinich et al., 2003; Mori et al., 2003; Notohami-
prodjo et al., 2005). However, high expression of CXCR5 has
been detected in an involved lymph node, and CTCL-derived
HUT78 cells express both surface protein and mRNA for
CXCR5 (Notohamiprodjo et al., 2005). To our knowledge,
CXCR5 protein expression has not yet been described in SS.
CD62L
Transcripts for CD62L (L-selectin/SELL) were detected in 64%
of samples, but the expression levels were low in most
patients. Only two cases had levels 410-fold compared to
normal controls suggesting that most neoplastic T cells may
not express CD62L on the cell surface, or at best, only a low
level of expression. Immunohistochemical studies on skin
lesions of MF indicate that neoplastic T cells are typically
deficient in CD62L expression (Wood et al., 1990; Magro
et al., 2005), but it is unclear whether this is due to an
accumulation of neoplastic cells that lack CD62L or whether
CD62L is shed upon activation in the skin. (Rijlaarsdam et al.,
1990; Chao et al., 1997) With regard to circulating neoplastic
T cells, there is some evidence that CD62L surface protein is
also under expressed, but direct analysis on neoplastic cells is
limited (Wood et al., 1990; Borowitz et al., 1993). Only one
case of SS has been reported in which CD62L expression was
studied on Vbþ neoplastic T cells, and in this case, 95% of
the Vb17þ neoplastic cells in the blood expressed CD62L
(Hwang and Fitzhugh, 2001).
In normal individuals, the majority of CLAþ cells in the
blood also express high levels of CD62L (Picker et al., 1990).
The loss of CD62L has been associated with TH1-type CD4þ
memory T cells (Kanegane et al., 1996). Because the neoplastic
cells of SS are CD4þCLAþ cells with a TH2-polarized
phenotype, one would expect CD62L to be expressed.
However, in concert with the concept that T-memory cells
can be classified into nonpolarized central memory T cells that
co-express CD62L and CCR7 and fully differentiated effector
memory T cells that have lost both surface markers but capable
of performing immediate effector cell functions, loss of CD62L
on neoplastic T cells might be explainable. Indeed, recent
animal studies indicate that an intermediate memory T-cell
population defined as CD62LCCR7þ that exists between the
classic central memory T cells and effector memory T cells
(Unsoeld and Pircher, 2005). In this regard, 16 of 28 samples
had detectable gene transcripts for both CD62L and CCR7
followed by CD67LCCR7þ cells (n¼ 9). These results
suggest that neoplastic T cells are differentiated as central
memory T cells or intermediate memory T cells, and only one
case had the phenotype of effector memory T cells.
The results from the present studies indicate that variable
level of gene transcription is detectable in a most cases of
leukemic phase CTCL for several inducible inflammatory
chemokine receptors and for CD62L. Specifically, high trans-
cript levels were found for CCR10 (all samples), CXCR3 (75% of
samples), and CCR4 (54% of samples), and moderate levels of
gene message were also found for CCR7 (89% of samples),
results supported by studies in the literature that involve
detection of surface protein. Low transcript levels were found
for CCR1 (74% of samples), CXCR5 (50% of samples), and
CD62L (64% of samples), and most other studies have found an
absence of protein expression for these markers. Negligible gene
expression was found for CCR5 and CCR6. Thus, there would
appear to be good correlation between gene expression levels
and protein expression if one assumes detection of mRNA
transcripts is more sensitive than detection of surface protein
expression and expression can vary among cases.
Considering the important role that chemokines play in the
lymphocyte trafficking, the main goal of this study was to
correlate chemokine receptor and CD62L expression with
clinical and pathological parameters. We limited this analysis
to patients with SS to provide a uniform clinical subset.
Relatively high expression levels of CCR7 and CCR10 by
circulating neoplastic T cells correlated with epidermotrop-
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ism, CXCR5 expression correlated with density of the dermal
infiltrate with both parameters associated with an adverse
prognosis, and CD62L correlated with extent of lymphadeno-
pathy. The associations between CCR10 and epidermotrop-
ism and between CD62L and extensive lymphadenopathy are
not surprising considering that CCL27/CTACK, the chemo-
kine agonist for CCR10, is secreted by keratinocytes (Fujita
et al., 2006), and CD62L binds to peripheral node addressin
expressed by HEVs in lymph nodes, a necessary step for entry
of T cells into lymph nodes. Because HEVs may also be
expressed by dermal vessels in CTCL, a potential mechanism
exists for CD62Lþ neoplastic cells to enter the skin (Michie
et al., 1993; Lechleitner et al., 1999). However, because the
level of gene expression of CD62L was low, the correspond-
ing surface protein might be too low to play a substantial role
in trafficking into the skin. Alternatively, adequate levels
of CD62L surface protein may be expressed by neoplastic
T cells to allow tethering with HEVs and subsequent entry
into lymph nodes and the skin, but the protein is shed from
the surface upon activation in these environments. (Rijlaars-
dam et al., 1990; Chao et al., 1997) Finally, the associations
between CCR7 and epidermotropism and CXCR5 and dermal
infiltration are not as evident and warrant further discussion.
Although CCR7 may be involved in entry of lymphocytes
into the skin in some circumstances (Serra et al., 2004), the
main function of CCR7 is to regulate T-lymphocyte egress
from the skin and subsequent migration into the draining
lymph node (Debes et al., 2005). In this regard, it was
interesting that relatively high CCR7 transcript levels (median
levels or higher) did not correlate with pattern of dermal
infiltrate, but did correlate to the degree of epidermal
infiltration. To our knowledge, CCL19, the chemokine ligand
for CCR7, is not expressed by keratinocytes so the reason for
the observed correlation between high CCR7 and epidermal
infiltration is unclear. It may be that CCR7þ neoplastic
T cells that enter the skin readily return to the blood, leaving
behind cells that remain in the epidermis. Because no
correlation was apparent between expression levels of
CCR7 and CCR10 (n¼25, r¼0.142, P¼ 0.493), it is unlikely
that the association between CCR7 and epidermotropism is
an epiphenomenon. The possibility that maturing dendritic
cells might be a source for CCL19 must be considered
because of its suspected role in certain chronic inflammatory
diseases (Kaiser et al., 2005; Radstake et al., 2005; Ichimura
et al., 2006). In nonmalignant inflammatory skin diseases,
CCL19 has rarely been found on infiltrating cells including
dendritic cells (Christopherson et al., 2003; Katou et al.,
2003). However, CCL19 production by dendritic cells is
particularly responsive to CD40 ligation (Vissers et al., 2001),
and because CD40 ligand is expressed by neoplastic T cells
in MF (Carbone et al., 1995; Mori et al., 1997; Storz et al.,
2001) and to a lesser degree in SS (Kamarashev et al., 1998;
French et al., 2005), it may be that the initial interactions
between CD40L-bearing neoplastic T cells and maturing
Langerhans cells in the epidermis promote CCL19 release
and recruitment of additional CCR7þ neoplastic cells into
the epidermis. The observation that CD40L is lost in
the tumor phase of MF could provide another mechanism
for the loss of epidermotropism in advanced disease
(Mori et al., 1997).
CXCL13, the chemokine for CXCR5, functions as an arrest
chemokine in the binding of B cells to lymph node HEVs and
because similar structures are present in the skin of MF
lesions, CXCL13 could also play a role in skin homing
(Kanemitsu et al., 2005). In SS, neoplastic T cells tend to
localize around vessels in the superficial vascular plexus
(Diwan et al., 2005). However, CXCL13 was not identified in
four cases of MF studied at the immunohistochemical or
molecular level by Mori et al. (2003). On the other hand,
other investigators have shown that human monocytes/
macrophages are a potent inducible source of CXCL13 in
inflammatory lesions where lymphoid neogenesis occurs
(Carlsen et al., 2004). In view of the chronic inflammatory
nature of SS, local production of CXCL13 by tissue macro-
phages might account for the association between CXCR5
expression by circulating neoplastic T cells and the degree of
dermal infiltration in the skin.
Considering the fact that both the magnitude of cellular
infiltration in the dermis of SS and the presence of CXCR5
transcripts in circulating neoplastic cells are associated with a
worse prognosis, and that CXCR5 expression also correlates
with density of the dermal infiltrate, we hypothesize that
neoplastic T cells upon entering the skin receive growth
enhancing stimulation from dendritic cells and as a con-
sequence transiently express CXCR5 which can be detected
at the gene expression level in some cells that re-enter the
circulation. Other chemokine receptors that might potentially
be involved in skin-homing of neoplastic T cells are CXCR3
and CD62L, but neither correlated with the pattern of dermal
or epidermal infiltration in our patients.
CXCR3/CD183 is a chemokine receptor with selectivity
for three CXC chemokines, termed IP10 (IFN-g-inducible
10 kDa protein), Mig (monokine induced by IFN-gg), and I-
TAC (IFN-inducible T-cell a-chemoattractant). IP10, Mig, and
I-TAC are commonly produced by local cells in inflammatory
lesions. In MF/SS, the epidermis provides a source of
CXCL10/IP10 that is thought to play a role in the characteris-
itic epidermotropism of neoplastic T cells (Sarris et al., 1997;
Tensen et al., 1999). The lack of an association between
CXCR3 transcript levels and epidermotropism might be
related to the fact that SS is a TH2-polarized disease and
therefore IFN-g-induced chemokines such as CXCL10 might
not be contributing as much to epidermal homing compared
to other chemokines such as CCL27/CTACK (via CCR10)
appear to play in this setting.
MATERIALS AND METHODS
Real-time qPCR was performed on samples of peripheral blood
lymphocytes from 28 patients with leukemic CTCL as defined using
hematologic criteria recommended by the ISCL (Vonderheid et al.,
2002). Samples from three additional patients (PT4, PT12, and PT19)
were excluded because the mRNA in the sample had degraded.
Twenty-six samples with usable mRNA were collected by leuko-
pheresis between November 1989 and September 1997 and stored
in liquid nitrogen, and two additional samples (PT30 and PT31) were
obtained from recently evaluated patients (Table 1). Twenty-five
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cases had generalized erythroderma (T4 skin rating) and therefore
fulfilled the ISCL definition of SS (Vonderheid et al., 2002). The
remaining three patients also had leukemic involvement, but had
skin manifestations of extensive MF (PT20 and PT27) or primary
cutaneous peripheral T-cell lymphoma with histologic features
resembling Kimura’s disease (PT28). Blood samples from five healthy
individuals (three men, two women) between the ages of 30 and 58
years were used as normal controls. These blood samples were
collected under adherence to the Declaration of Helsinki Principles
after informed consent was obtained and the research was approved
by the Institutional Review Board of Johns Hopkins University.
The immunophenotype of the neoplastic cells in all cases was
CD3þCD4þCD8 with a CD4/CD8 ratio of 10 or more at the time
of collection for 21 (75%) cases. Absolute absolute Se´zary cell
counts exceeded 1.0 K/ml in 20 (71%) of the cases, and absolute
lymphocyte counts exceeding 4.0 K/ml occurred in 13 patients of
which 10 had evidence of a dominant T-cell clone by Southern blot
(three cases), PCR analysis of the T-cell receptor g-chain (five cases)
or both methods (two cases). Chromosome studies showed an
abnormal clone in the blood for 23 (82%) cases. Taken together, four
patients had one ISCL criterion for leukemic involvement, five
patients had two criteria, four patients had three criteria, eight
patients had four criteria and seven patients had all five criteria
(Vonderheid et al., 2002).
qPCR reactions were performed with use of TaqMan assay
(Applied Biosystems Inc., Foster City, CA) and PCR amplifications in
ABI PRISM 7000 Sequence Detection System (Applied Biosystems)
as described previously (Miura et al., 2002, 2004). Threshold cycle
(CT) during the exponential phase of amplification was determined
by real-time monitoring of fluorescent emission after cleavage of
sequence-specific probes by nuclease activity of Taq polymerase.
Target gene expression (CCR1, CCR4, CCR5, CCR6, CCR7, CCR10,
CXCR3, CXCR5, and CD62L) was assessed by qPCR using an ABI
PRISM 7000 Sequence Detection System and reagents (primers,
probes) purchased from Applied Biosystems Inc. as described
previously (Miura et al., 2002, 2004). Glyceraldehyde-3-phosphate
dehydrogenase was used as an internal control gene for mRNA
expression. Relative transcripts were determined by the formula:
1/2(CTtargetCTcontrol). Primers and probe were designed so that
amplicons spanned intron/exon boundaries to minimize amplifica-
tion of genomic DNA. Real-time PCR efficiencies of target genes,
that is CCR1) and the reference gene (glyceraldehyde-3-phosphate
dehydrogenase) were approximately equal over a concentration of
0.1–200 ng total cDNA.
Statistical analysis
Because most continuous variables did not have a normal
distribution, nonparametric tests (Mann–Whitney and Kruskal–Wallis
tests) were used to test for differences among two and three or more
groups, respectively. Fisher’s and Pearson’s w2 exact tests were used
to test categorical data in 2 by 2 and R by C tables, respectively. The
Cox proportional hazards model was used to examine the relation-
ship between prognostic factors and survival. For some continuous
variables, optimal discriminate cut points were established from
normal laboratory reference values, cut points used in other studies
or by preliminary univariate analysis of categorized data. Only
factors with statistical significance on univariate analysis were
entered into multivariate analysis. Survival probabilities were
calculated using the method of Kaplan–Meier and survival curves
were compared using the log-rank test of Mantel–Cox. Survival was
determined from time of blood sampling to the death of death or last
known date alive. Censoring was not required because the status of
each patient was known at the time of the analysis. Death from any
cause used to define overall survival. The statistical packages used
for data analysis and graphs were SYSTAT10 and SPSS 13.0 for
Windows (SPSS Inc., Chicago, IL), StatXact 6 and EGRET for
Windows (Cytel Inc., Cambridge, MA), and SigmaPlot 9.0 (Systat
Software Inc., Point Richman, CA).
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